AstraZeneca announces the latest phase 3 clinical results of the new crown vaccine

Today, AstraZeneca announced that the new crown vaccine AZD1222 jointly developed by the company and the University of Oxford has obtained positive results in a phase 3 clinical trial conducted in the United States.

In previous phase 3 clinical trials conducted in the United Kingdom, South Africa and Brazil, two doses of AZD1222 vaccine were administered 21 days apart, and the effectiveness of preventing symptomatic COVID-19 was 62.

The study was conducted in the United States, Peru, and Chile, and a total of 32,449 subjects were recruited.

Among the subjects participating in the clinical trials, nearly 20% are elderly people over 65, and nearly 60% carry comorbidities that may increase the risk of COVID-19 progressing to serious diseases, including diabetes, severe obesity, or heart disease.

Based on recent reports of thrombotic events, the Independent Data Security Monitoring Committee specifically reviewed thrombotic events, including the review of cerebral venous sinus thrombosis (CVST) with the assistance of an independent neurologist.

A few days ago, the British Medicines and Health Products Administration (MHRA) and the European Medicines Agency (EMA) have announced that the benefits of AstraZeneca’s new crown vaccine outweigh the risks.

Note: The original text has been deleted

Reference materials:

[1] UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective.

[2] AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis.